Table 4.
MSP2 (3D7 Allele) | All Samples | Aparasitemic | Parasitemic | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 y | 1–3 y | 4–6 y | 7–10 y | P Valuea | 0 y | 1–3 y | 4–6 y | 7–10 y | P Valuea | 0 y | 1–3 y | 4–6 y | 7–10 y | P Valuea | ||
May 2002b | No.c | 30 | 128 | 117 | 23 | 30 | 109 | 93 | 15 | 0 | 19 | 24 | 8 | |||
Median | 0.04 | 0.13 | 0.33 | 0.33 | <.001 d | 0.04 | 0.10 | 0.28 | 0.29 | <.001 d | 0.00 | 0.89 | 1.14 | 1.76 | .640 | |
IQR | (0.02–0.13) | (0.03–0.4) | (0.12–1.09) | (0.11–1.29) | (0.02–0.13) | (0.03–0.3) | (0.12–0.82) | (0.11–0.87) | (0–0) | (0.58–1.58) | (0.16–2.08) | (0.33–2.43) | ||||
October 2002b | No.c | 37 | 110 | 108 | 36 | 36 | 105 | 99 | 31 | 1 | 5 | 9 | 5 | |||
Median | 0.04 | 0.05 | 0.14 | 0.14 | <.001 d | 0.04 | 0.04 | 0.13 | 0.12 | <.001 d | 0.01 | 0.62 | 0.21 | 1.65 | .193 | |
IQR | (0.01–0.1) | (0.02–0.09) | (0.06–0.34) | (0.07–0.47) | (0.02–0.1) | (0.02–0.08) | (0.06–0.33) | (0.07–0.34) | (0.01–0.01) | (0.04–0.77) | (0.14–0.54) | (0.5–2.43) | ||||
May 2003b | No.c | 27 | 102 | 105 | 51 | 26 | 93 | 88 | 40 | 1 | 9 | 17 | 11 | |||
Median | 0.09 | 0.04 | 0.13 | 0.13 | <.001 d | 0.10 | 0.04 | 0.10 | 0.14 | <.001 d | 0.06 | 0.12 | 0.73 | 1.16 | .048 d | |
IQR | (0.01–0.23) | (0.01–0.1) | (0.05–0.43) | (0.07–0.72) | (0.01–0.23) | (0.01–0.09) | (0.04–0.31) | (0.06–0.31) | (0.06–0.06) | (0.04–0.26) | (0.2–1.39) | (0.2–2.56) | ||||
October 2003b | No.c | 23 | 103 | 110 | 58 | 23 | 93 | 91 | 45 | 10 | 18 | 13 | 0 | |||
Median | 0.08 | 0.06 | 0.13 | 0.13 | <.001 d | 0.08 | 0.06 | 0.10 | 0.18 | <.001 d | 0.43 | 0.49 | 1.77 | 0.00 | .426 | |
IQR | (0.04–0.19) | (0.02–0.25) | (0.05–0.41) | (0.08–0.56) | (0.04–0.19) | (0.01–0.16) | (0.04–0.28) | (0.07–0.44) | (0.29–1.03) | (0.32–0.75) | (0.32–2.17) | (0–0) | ||||
May 2004b | No.c | 21 | 93 | 86 | 79 | 21 | 88 | 84 | 69 | 0 | 5 | 2 | 10 | |||
Median | 0.01 | 0.04 | 0.08 | 0.08 | <.001 d | 0.01 | 0.03 | 0.08 | 0.17 | <.001 d | 0.00 | 0.22 | 0.49 | 0.43 | .809 | |
IQR | (0–0.02) | (0–0.1) | (0.04–0.24) | (0.06–0.6) | (0–0.02) | (0–0.09) | (0.04–0.23) | (0.04–0.47) | (0–0) | (0.2–1.53) | (0.25–0.72) | (0.17–2.14) | ||||
October 2004b | No.c | 15 | 84 | 87 | 87 | 15 | 80 | 87 | 81 | 0 | 4 | 0 | 6 | |||
Median | 0.02 | 0.04 | 0.07 | 0.07 | <.001 d | 0.02 | 0.03 | 0.07 | 0.13 | <.001 d | 0.00 | 0.45 | 0.00 | 1.63 | .088 | |
IQR | (0.01–0.06) | (0.01–0.08) | (0.03–0.14) | (0.05–0.45) | (0.01–0.06) | (0.01–0.07) | (0.03–0.14) | (0.05–0.37) | (0–0) | (0.13–1.33) | (0–0) | (1.17–2.31) |
Abbreviation: IQR, interquartile range.
a P values calculated using a Kruskal–Wallis test (P ≤ .05 indicated in bold type).
bCross-sectional survey.
cNumber of samples tested by enzyme-linked immunosorbent assay. Data on antibodies to the FC27 allele of MSP2 are provided in the Supplementary Materials.
d P ≤ .05 when comparing antibody levels between children aged 1–3 years and children aged 7–10 years using a Mann–Whitney U test (P values not shown).